Baralgin M, 500 mg/ml 5 pcs.

Baralgin is antispasmodic, analgesic, antipyretic, anti-inflammatory.

Blocks cyclooxygenase and reduces GH synthesis.

Pharmacokinetics

. After oral administration, it is hydrolyzed in the gastrointestinal tract to form the active metabolite, 4-methylaminoantipyrine (4-MMA), which is absorbed in the liver to 4-aminoantipyrine (4-AA), as well as pharmacologically inactive metabolites. After ingestion of 1 g of metamizole, 58% of 4-MMA and 48% of 4-AA are bound to plasma proteins. Effective therapeutic plasma concentration of 4-MMA is reached after 20-40 min, Cmax – after 2 h.

Indications

pain of various origins
spasms of internal organs (renal colic, biliary colic)
postoperative pain. spasms of cerebral vessels.

Pharmacological effect

Baralgin – antispasmodic, analgesic, antipyretic, anti-inflammatory.

Blocks cyclooxygenase and reduces PG synthesis.

Pharmacokinetics

After oral administration, it is hydrolyzed in the gastrointestinal tract to form an active metabolite – 4-methylaminoantipyrine (4-MMA), which is absorbed in the liver into 4-aminoantipyrine (4-AA), as well as pharmacologically inactive metabolites. After oral administration of 1 g of metamizole, 58% of 4-MMA and 48% of 4-AA are bound to plasma proteins. The effective therapeutic concentration in plasma of 4-MMA is achieved after 20–40 minutes, Cmax after 2 hours.

Special instructions

In patients suffering from bronchial asthma, taking the drug can provoke the development of an attack.

Active ingredient

Metamizole sodium

Composition

1 ml of solution contains metamizole sodium 500 mg;

Contraindications

agranulocytosis
coronary heart disease
glaucoma
prostate adenoma
severe hepatic-renal failure
hypersensitivity to the components of the drug.

Side Effects

decrease in the number of leukocytes in the blood
drop in blood pressure
renal dysfunction
allergic reactions.

Interaction

The simultaneous use of metamizole with other non-narcotic analgesics can lead to mutual enhancement of toxic effects.

Tricyclic antidepressants, oral contraceptives, and allopurinol disrupt the metabolism of metamizole in the liver and increase its toxicity.

Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effect of metamizole. Sedatives and tranquilizers enhance the analgesic effect of the drug. Concomitant use with chlorpromazine or other phenothiazine derivatives can lead to the development of severe hyperthermia.

Radiocontrast agents, colloidal blood substitutes and penicillin should not be used during treatment with metamizole.

Metamizole, displacing oral hypoglycemic drugs, indirect anticoagulants, glucocorticosteroids and indomethacin from protein binding, increases their activity.

Myelotoxic drugs enhance the hematotoxicity of the drug.

Due to the high probability of pharmaceutical incompatibility, it should not be mixed with other drugs in the same syringe.

Overdose

Symptoms: nausea, vomiting, gastralgia, oliguria, hypothermia, decreased blood pressure, tachycardia, shortness of breath, tinnitus, drowsiness, delirium, impaired consciousness, acute agranulocytosis, hemorrhagic syndrome, acute renal and/or liver failure, convulsions, paralysis of the respiratory muscles.

Treatment: induction of vomiting, transtube gastric lavage, saline laxatives, activated charcoal; carrying out forced diuresis, hemodialysis, with the development of convulsive syndrome – intravenous administration of diazepam and fast-acting barbiturates.

Storage conditions

In a place protected from light, at a temperature of 8–25 °C

Shelf life

4 years.

Manufacturer

Elysium Pharmaceuticals Ltd., India